Recombinant influenza virus for expressing PD-1 humanized antibody and preparation and application thereof

By inserting the antibody gene into the influenza virus gene, recombinant influenza virus is constructed, and the problem of limited indications in tumor treatment is solved, and PD-1 human monoclonal antibody that efficiently expresses functional activity in the body is used for Treatment of various diseases.

CN118956782APending Publication Date: 2024-11-15BEIJING SUBENYUANHE BIOTECHNOLOGY CO LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202411444652.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-16
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Among the existing tumor treatments, the indications for therapeutic drugs for PD-1-related tumor types are limited, and traditional antibody drugs have insufficient specificity and stability, making it difficult to meet the needs of a variety of specific indications.

Method used

By using the packaging signal sequences of the polymerase genes PB1 and PA of influenza A virus, the encoding antibody gene was inserted into the influenza virus gene to construct a recombinant influenza virus. The virus was used as a vector to express functional activity in vivo PD-1 human single Cloning antibodies to achieve treatment for specific tumors.

Benefits of technology

It realizes efficient expression of PD-1 human monoclonal antibody with biological activity in the body, has the same biological activity as homologous antibodies, is suitable for the prevention and treatment of various diseases, and has become a new tumor immunotherapy method. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956782A_ABST
    Figure CN118956782A_ABST
Patent Text Reader

Abstract

The invention provides a recombinant influenza virus for expressing a PD-1 human antibody, which comprises a fusion gene PB1-PD-1-VL consisting of a PB1 gene, a mutated PB-1 packaging sequence, an FMDV-2A sequence, a signal peptide sequence, a PD-1 human antibody VL gene and a light chain kappa gene, and a fusion gene PA-PD-1-VH composed of a PA gene, a mutant PA packaging sequence, an FMDV-2A sequence, a signal peptide sequence, a PD-1 human antibody VH gene, a heavy chain CH1 gene and an Fc gene. The recombinant influenza virus can stably express the PD-1 humanized antibody in multiple passages, and a novel drug is provided for cancer treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field The present application belongs to the field of biotechnology and tumor treatment. Specifically, the present application provides a recombinant influenza virus expressing humanized PD-1 antibody and its preparation and application. Background Art Influenza viruses are widely prevalent in poultry, mammals and humans. They have a wide host distribution and mutate quickly, often bringing a large disease burden to humans and animal husbandry such as poultry and pigs. From the perspective of virus taxonomy, influenza viruses are enveloped RNA viruses, and their RNA is negative stranded. The inner core of the influenza virus particle is a ribosomal nucleoprotein wrapped with single-stranded RNA, and the inner outer core is wrapped with matrix protein M1. The influenza virus genome consists of eight segmented linear gene fragments (influenza C virus has only seven gene fragments), and the eight gene fragments encode ten proteins, namely: RNA-dependent RNA polymerase (PB2, PB1, PA), nucleoprotein NP that forms the nucleocapsid, matrix membrane protein (M1, M2), two surface membrane proteins (hemagglutinin HA and neuraminidase NA), non-structural protein NS1 and nuclear export protein NEP. The transcription and replication of viral genes occur in the host cell nucleus, and the virus assembles and buds on the host cell membrane. Gene reassortment occurs when two different influenza viruses infect a cell at the same time. The eight gene segments of influenza virus encode a total of nine structural proteins (PB2, PB1, PA, HA, NP, NA, M1, M2, NEP) and one non-structural protein NS1. Influenza viruses produce many natural gene deletions or insertions during genetic evolution, but deletions are the most common. These deletions or insertions play an important role in the pathogenicity of the virus, the expansion of the host range, and the adaptation to new hosts. Gene deletions are mainly concentrated in the NA gene and the NS1 gene, especially in animal-derived influenza viruses, which often occur during the process of infecting and adapting to new hosts, and the specific location and number of deletions vary between different strains. Insertions mainly occur when low-pathogenic influenza viruses become highly pathogenic influenza viruses, and multiple basic amino acids, such as KRRK, are inserted before the cleavage site / GLF motif of the HA gene. This type of insertion of multiple basic amino acids in the HA protein only occurs in H5 and H7 subtype influenza viruses. These deletions and insertions of influenza viruses indicate that the genome of the virus can tolerate mutations at these positions, so people try to modify influenza viruses through the positions of deletions, such as NS1 gene deletion viruses.

[0003] At the same time, studies have shown that foreign genes, such as the human interleukin 15 (IL15) gene, can be added to the NS1 deletion region. Such recombinant viruses can express the target protein IL15, thereby using the influenza virus as an expression system for foreign genes and playing a certain role in immune regulation in vivo. By taking advantage of the NA deletion and adding the GFP protein gene to the NA gene, the recombinant influenza virus can express GFP during replication, and the recombinant virus has biological characteristics similar to those of the wild virus, so that the virus can be visualized when it infects the body. The foreign genes carried by the modified influenza virus are mostly used as more sensitive reporter viruses to screen antiviral drugs or study pathogenic mechanisms.

[0004] PD-1 is the abbreviation of Progrma death 1 molecule, which is an important immunosuppressive transmembrane protein expressed on the surface of T cells. PD-1 mainly limits the activity of T cells in chronic inflammation, infection or cancer. PD-1 has two ligands, PD-L1 and PD-L2. In the microenvironment of the tumor, tumor cells can express PD-L1 or PD-L2. Currently, a variety of anti-PD-1 monoclonal antibody drugs have been launched on the market, and more than ten indications have been approved by the FDA. For example, the latest indication approved by the FDA for KEYTRUDA (anti-PD-1 monoclonal antibody drug produced by MSD) is based on biomarkers rather than specific tumor types. Summary of the invention

[0005] The present invention utilizes the packaging signal sequence of influenza A virus polymerase gene PB1 and PA, and respectively loads the genes encoding antibody gene variable regions VL and VH into influenza virus PB1 and PA genes, rescues and packages recombinant influenza viruses with infection and replication activity through infectious cloning technology, and simultaneously expresses functionally active monoclonal antibodies during the replication of the recombinant virus. The recombinant influenza virus involved in the present invention has biological characteristics similar to those of wild influenza A virus: low pathogenicity, unchanged in vivo and in vitro replication titer. The expressed medicinal antibody has the same biological activity as the antibody drug encoded by the same gene, and can be used for disease prevention and treatment for specific indications. Therefore, the recombinant influenza virus can be used to express antibodies, treat infectious diseases, autoimmune diseases, neurodegenerative diseases, tumors and other indications, and become one of the important components of viral immunotherapy drugs.

[0006] In the past, the method of using influenza virus as a vector to express foreign proteins has focused on the positions where natural deletions occur in the influenza A virus genome, such as NA and NS1. Deletions at these positions indicate that the virus can tolerate some mutations, but the foreign gene fragment that can be inserted should not be too large, and there is no need to modify the 3' and 5' packaging signals, that is, 3' packaging signal sequence-viral gene ORF-(2A) foreign protein gene sequence-5' packaging signal sequence. Such recombinant viruses are mostly used in reporter virus systems, that is, viruses express GFP or luciferase, etc. (Ref). The genetic stability of its foreign genes, viral replication and other biological properties are the same as those of wild viruses.

[0007] The present invention utilizes the 5'-end packaging signal sequence of mutation PB1 and PA (ensuring that the amino acid sequence remains unchanged and the third position of the nucleotide sequence is mutated) to make them lose the packaging signal recognition function, and clones the heavy chain variable region-Fc gene and the light chain variable region gene-kappa / lambda gene encoding human monoclonal antibodies to the 5'-end of the complete genes of PA and PB1 respectively, adds a 2A sequence that can be cut between them, and then adds the corresponding 5'-end packaging signal sequence. The vRNA of the virus PB1 and PA carries the genes of the antibody VL and VH respectively, and the recombinant influenza virus is rescued through the eight-plasmid reverse genetic system. During the whole process, the exogenous antibody gene can be replicated, transcribed, expressed, cut, and packaged into the progeny virus particles. After the antibody gene is expressed during the infection process, a functional human IgG antibody can be formed, and the purified antibody is reacted with the corresponding antigen through ELISA to determine its biological activity.

[0008] On the one hand, the present application provides a recombinant influenza virus expressing a humanized PD-1 antibody, wherein the recombinant influenza virus comprises a fusion gene PB1-PD-1-VL and a fusion gene PA-PD-1-VH; The fusion gene PB1-PD-1-VL includes, from the 5' end, the PB1 gene, the mutated PB-1 packaging sequence, the FMDV-2A sequence, the signal peptide sequence, the PD-1 human antibody VL gene, and the light chain kappa gene; The fusion gene PA-PD-1-VH includes, from the 5' end, the PA gene, the mutated PA packaging sequence, the FMDV-2A sequence, the signal peptide sequence, the PD-1 human antibody VH gene, the heavy chain CH1 gene and the Fc gene.

[0009] Furthermore, the PB1 gene sequence of the fusion gene PB1-PD-1-VL is shown in SEQ ID NO.4, the mutated PB-1 packaging sequence is shown in SEQ ID NO.14, the FMDV-2A sequence is shown in SEQ ID NO.15, and the signal peptide sequence is shown in SEQ ID NO.16; The PA gene sequence of the fusion gene PA-PD-1-VH is shown in SEQ ID NO.5, the mutated PA packaging sequence is shown in SEQ ID NO.9, the FMDV-2A sequence is shown in SEQ ID NO.10, and the signal peptide sequence is shown in SEQ ID NO.11 Furthermore, the PD-1 human antibody is KEYTRUDA.

[0010] Furthermore, the PD-1 human antibody VL gene of the fusion gene PB1-PD-1-VL is shown in SEQ ID NO.17, and the light chain kappa gene is shown in SEQ ID NO.18; The PD-1 human antibody VH gene of the fusion gene PA-PD-1-VH is shown in SEQ ID NO.12, and the heavy chain CH1 gene and Fc gene are shown in SEQ ID NO.13 Furthermore, the recombinant influenza virus expressing the humanized PD-1 antibody also includes influenza virus PB2, HA, NP, NA, M and NS genes.

[0011] On the other hand, the present application provides a method for preparing the above-mentioned recombinant influenza virus expressing the PD-1 human antibody, wherein the method is to rescue and prepare the recombinant influenza virus expressing the PD-1 human antibody through an eight-plasmid reverse genetics system.

[0012] Furthermore, the method includes mixing a plasmid carrying influenza virus PB2, HA, NP, NA, M and NS genes and a plasmid carrying fusion gene PB1-PD-1-VL and fusion gene PA-PD-1-VH with liposomes and then incubating with 293T cells.

[0013] On the other hand, the present application provides the use of the above-mentioned recombinant influenza virus expressing human PD-1 antibody in the preparation of a drug for treating cancer.

[0014] Furthermore, the cancer is a PD-1 associated cancer.

[0015] The cancer associated with PD-1 is a tumor associated with high expression of PD-1 discovered in the prior art or in clinical treatment, including but not limited to lung cancer, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, bone cancer, esophageal cancer, oral cancer, skin cancer, etc.

[0016] On the other hand, the present application provides the use of the above-mentioned recombinant influenza virus expressing PD-1 human antibody in the preparation of PD-1 human antibody. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 Schematic diagram of the basic structure of influenza virus for the construction of human monoclonal antibodies; Figure 2 This is a schematic diagram of the construction of PD-1 monoclonal antibody gene; Figure 3 This is the result of PCR detection of antibody genes in the continuous passage of recombinant virus; Figure 4 These are the activity results of PD-1 monoclonal antibodies expressed by recombinant influenza viruses. DETAILED DESCRIPTION

[0018] Example 1 Construction of various recombinant vectors The pHW2000 empty vector is described in the following literature: A DNA transfection system for generation of influenza A virus from eight plasmids. PNAS (97) 11;6108-6113; the public can obtain it from Zoonogen Innovation Research Center. Bsm The sequences of the BI recognition site were transformed into the universal sequences of influenza A virus, uni12 (5-'AGCGAAAGCAGG-3') and uni13 (5'-AGTAGAAACAAGG-3'). After the uni12 and uni13 sequences were connected, a StuI recognition sequence (AGG / CCT) was formed in the middle. This vector was named pHKU_FluA vector, which is recorded in the following literature, Multiple basic amino acids in the cleavage site of H7N9 hemagglutinin contribute to high virulence in mice JThorac Dis 2021;13(8):4650-4660. The public can obtain it from the Zoonogen Innovation and Research Center.

[0019] For pHKU_FluA vector and rCutSmart restriction buffer, Stu I 10U, total volume 50µL, 37°C overnight digestion. The fragment of about 3000 was recovered from the electrophoresis gel, which was the linearized pHW2000 vector. The linearized fragment and the PCR product of the HA gene from A / PR / 8 / 1934 (H1N1) were infused to obtain the recombinant vector pHW2000-PR8_HA (after sequencing, the vector was obtained by inserting the H1 gene shown in sequence 1 into the pHW2000 vector); Sequence 1: pHW2000-PR8_HA use Stu I linearized pHW2000 vector and connected it with the NA gene PCR product derived from A / PR / 8 / 1934 (H1N1) by infusion to obtain the recombinant vector pHW2000-PR8_NA (after sequencing, the vector was obtained by inserting the NA gene shown in sequence 2 into the pHW2000 vector); Sequence 2: pHW2000-PR8_NA use Stu I linearized pHW2000 vector and connected it with the PCR product of PB2 gene from A / PR / 8 / 1934 (H1N1) by infusion to obtain the recombinant vector pHW2000-PR8_PB2 (after sequencing, the vector was obtained by inserting the gene PB2 shown in sequence 3 into the pHW2000 vector); Sequence 3: pHW2000-PR8_PB2 use Stu I. Linearize the pHW2000 vector and perform infusion connection with the PCR product of the PB1 gene derived from A / PR / 8 / 1934 (H1N1) to obtain the recombinant vector pHW2000-PR8_PB1 (after sequencing, the vector is a recombinant vector obtained by inserting the gene PB1 shown in sequence 4 into the pHW2000 vector); Sequence 4: pHW2000-PR8_PB1 use Stu I linearized pHW2000 vector and connected it with the PCR product of PA gene from A / PR / 8 / 1934 (H1N1) by infusion to obtain the recombinant vector pHW2000-PR8_PA (after sequencing, the vector was obtained by inserting the gene PA shown in sequence 5 into the pHW2000 vector); Sequence 5: pHW2000-PR8_PA use Stu I. Linearize the pHW2000 vector and perform infusion connection with the NP gene PCR product derived from A / PR / 8 / 1934 (H1N1) to obtain the recombinant vector pHW2000-PR8_NP (after sequencing, the vector is a recombinant vector obtained by inserting the gene NP shown in sequence 6 into the pHW2000 vector); Sequence 6: pHW2000-PR8_NP use Stu I linearized pHW2000 vector and connected it with the M gene PCR product derived from A / PR / 8 / 1934 (H1N1) by infusion to obtain the recombinant vector pHW2000-PR8_M (after sequencing, the vector was obtained by inserting the gene M shown in SEQ ID NO: 7 into the pHW2000 vector); Sequence 7: pHW2000-PR8_M use Stu I. Linearize the pHW2000 vector and perform infusion connection with the NS gene PCR product derived from A / PR / 8 / 1934 (H1N1) to obtain the recombinant vector pHW2000-PR8_NS (after sequencing, the vector is a recombinant vector obtained by inserting the gene NS shown in sequence 8 into the pHW2000 vector); Sequence 8: pHW2000-PR8_NS >agcaaaagcagggtgacaaaaacataatggatccaaacactgtgtcaagctttcaggtagattgctttctttggcatgtccgcaaacgagttgcagaccaagaactaggcgatgccccattccttgatcggcttcgccgagatcagaaatccctaagaggaaggggcagtactctcggtctggacatcaagacagccacacgtgctggaaagcagatagtggagcggattctgaaagaagaatccgatgaggcacttaaaatgaccatggcctctgtacctgcgtcgcgttacctaactgacatgactcttgaggaaatgtcaagggactggtccatgctcatacccaagcagaaagtggcaggccctctttgtatcagaatggaccaggcgatcatggataagaacatcatactgaaagcgaacttcagtgtgatttttgaccggctggagactctaatattgctaagggctttcaccgaagagggagcaattgttggcgaaatttcaccattgccttctcttccaggacatactgctgaggatgtcaaaaatgcagttggagtcctcatcggaggacttgaatggaatgataacacagttcgagtctctgaaactctacagagattcgcttggagaagcagtaatgagaatgggagacctccactcactccaaaacagaaacgagaaatggcgggaacaattaggtcagaagtttgaagaaataagatggttgattgaagaagtgagacacaaactgaagataacagagaatagttttgagcaaataacatttatgcaagccttacatctattgcttgaagtggagcaagagataagaactttctcgtttcagcttatttagtactaaaaaacacccttgtttctact Using the recombinant vector pHW2000-PR8_PA as a template, the mutated packaging sequence (CSPS), FMDV-2A sequence, signal peptide sequence, PD1 monoclonal antibody VH gene, heavy chain CH1 and Fc sequence, and PB8 virus PA gene packaging signal sequence were linked in sequence by the infusion method to obtain the recombinant vector pHW2000-PR8_PA-VH (after sequencing, the vector was obtained by inserting the following sequences into the pHW2000 vector in sequence); Sequence 9: Packing sequence (CSPS): CTCGAGCCAGGAACGTTCGACCTAGGAGGACTGTACGAGGCGATCGAAGAATGTCTCATAAACGACCCTTGGGTATTACTAAACGCATCATGGTTTAACTCGTTCCTGACTCACGCTTTAAGC Sequence 10: FMDV-2A: GGATCTGGAGCCACGAACTTCTCTCTGTTAAAGCAAGCAGGAGATGTTGAAGAAAACCCCGGGCCT Sequence 11, signal peptide sequence: ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCG Sequence 12, PD1 monoclonal antibody VH gene: CAAGTGCAACTTGTGCAATCAGGAGTGGAAGTGAAAAAACCAGGAGCATCAGTGAAAGTGTCATGCAAAGCATCAGGATATACATTCACAAATTATTATATGTATTGGGTGAGACAAGCACCAGGACAAGGACTTGAATGGATGGGAGGAATAAATCCATCAAATGGAGGAACAAATTTC AATGAAAAATTCAAAAATAGAGTGACACTTACAACAGATTCATCAACAACAACAGCATATATGGAACTTAAATCACTTCAATTCGATGATACAGCAGTGTATTATTGCGCAAGAAGAGATTATAGATTCGATATGGGATTCGATTATTGGGGACAAGGAACAACAGTGACAGTGTCATCA Sequence 13, heavy chain CH1 and Fc sequence: GCATCAACAAAAGGACCATCAGTGTTCCCACTTGCACCATGCTCAAGATCAACATCAGAATCAACAGCAGCACTTGGATGCCTTGTGAAAGATTATTTCCCAGAACCAGTGACAGTGTCATGGAATTCAGGAGCACTTACATCAGGAGTGCATACATTCCCAGCAGTGCTTCAATCATCAGGACTTTATTCACTTTCATCAGTGGTGACAGTGCCATCATCATCACTTGGAACAAAAACATATACATGCAATGTGGATCATAAACCATCAAATACAAAAGTGGATAAAAGAGTGGAATCAAAATATGGACCACCATGCCCACCATGCCCAGCACCAGAATTCCTTGGAGGACCATCAGTGTTCCTTTTCCCACCAAAACCAAAAGATACACTTATGATATCAAGAACACCAGAAGTGACATGCGTGGTGGTGGATGTGTCACAAGAAGATCCAGAAGTGCAATTCAATTGGTATGTGGATGGAGTGGAAGTGCATAATGCAAAAACAAAACCAAGAGAAGAACAATTCAATTCAACATATAGAGTGGTGTCAGTGCTTACAGTGCTTCATCAAGATTGGCTTAATGGAAAAGAATATAAATGCAAAGTGTCAAATAAAGGACTTCCATCATCAATAGAAAAAACAATATCAAAAGCAAAAGGACAACCAAGAGAACCACAAGTGTATACACTTCCACCATCACAAGAAGAAATGACAAAAAATCAAGTGTCACTTACATGCCTTGTGAAAGGATTCTATCCATCAGATATAGCAGTGGAATGGGAATCAAATGGACAACCAGAAAATAATTATAAAACAACACCACCAGTGCTTGATTCAGATGGATCATTCTTCCTTTATTCAAGACTTACAGTGGATAAATCAAGATGGCAAGAAGGAAATGTGTTCTCATGCTCAGTGATGCATGAAGCACTTCATAATCATTATACACAAAAATCACTTTCACTTTCACTTGGAAAA Using the recombinant vector pHW2000-PR8_PB1 as a template, the mutated packaging sequence (CSPS), FMDV-2A sequence, signal peptide sequence, PD1 monoclonal antibody VL gene, light chain kappa sequence, and PB8 virus PB1 gene packaging signal sequence were linked in sequence by the infusion method to obtain the recombinant vector pHW2000-PR8_PB1-VL (after sequencing, the vector was obtained by inserting the following sequences into the pHW2000 vector in sequence); Sequence 14, packaging sequence (CSPS): TCTAGGGCGCGTATCGACGCTCGCATCGACTTTGAGTCAGGTAGAATCAAAAAGGAGGAATTTACGGAAATCATGAAAATTTGCTCGACGATAGAGGAACTGAGGCGACAGAAA Sequence 15, FMDV-2A sequence: GGATCTGGAGCCACGAACTTCTCTCTGTTAAAGCAAGCAGGAGATGTTGAAGAAAACCCCGGGCCT Sequence 16, signal peptide sequence: ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCG Sequence 17, PD1 monoclonal antibody VL gene: GAAATAGTGCTTACACAATCACCAGCAACACTTTCACTTTCACCAGGAGAAAGAGCAACACTTTCATGCAGAGCATCAAAAGGAGTGTCAACATCAGGATATTCATATCTTCATTGGTATCAACAAAAACCAGGACAAGCACCAAGACTTCTTATAT ATCTTGCATCATATCTTGAATCAGGAGTGCCAGCAAGATTCTCAGGATCAGGATCAGGAACAGATTTCACACTTACAATATCATCACTTGAACCAGAAGATTTCGCAGTGTATTATTGCCAACATTCAAGAGATCTTCCACTTACATTCGGAGGAGGAACAAAAGTGGAAAATAAAA Sequence 18, light chain kappa sequence: GAAATAGTGCTTACACAATCACCAGCAACACTTTCACTTTCACCAGGAGAAAGAGCAACACTTTCATGCAGAGCATCAAAAGGAGTGTCAACATCAGGATTTCATATCTTCATTGGTATCAACAAAAACCAGGACAAGCACCAAGACTTCTT ATATATCTTGCATCATATCTTGAATCAGGAGTGCCAGCAAGATTCTCAGGATCAGGATCAGGAACAGATTTCACACTTACAATATCATCACTTGAACCAGAAGATTTCGCAGTGTATTATTGCCAACATTCAAGAGATCTTCCACTTACATTCGGAGGAGGAACAAAA GTGGAAATAAAAAGAACAGTGGCAGCACCATCAGTGTTCATATTCCCACCATCAGATGAACAACTTAAATCAGGAACAGCATCAGTGGTGTGCCTTCTTAATAATTTCTATCCAAGAGAAGCAAAAGTGCAATGGAAAGTGGATAATGCACTTCAATCAGGAAATTCA CAAGAATCAGTGACAGAACAAGATTCAAAAGATTCAACATATTCACTTTCATCAACACTTACACTTTCAAAAGCAGATTATGAAAAACATAAAGTGTATGCATGCGAAGTGACACATCAAGGACTTTCATCACCAGTGACAAAATCATTCAATAGAGGAGAATGCTAA in Identification and mutation of PB1 gene packaging signal, PR8 virus 5' packaging signal sequence: 5' packaging signal sequence 19: TCCAGAGCCCGAATTGATGCACGGATTGATTTCGAATCTGGAAGGATAAAGAAAGAAGAGTTCACTGAGATCATGAAGATCTGTTCCACCATTGAAGAGCTCAGACGGCAAAAATAG PB1 gene 5' packaging sequence 20 after mutation: TCTAGGGCGCGTATCGACGCTCGCATCGACTTTGAGTCAGGTAGAATCAAAAAGGAGGAATTTACGGAAATCATGAAAATTTGCTCGACGATAGAGGAACTGAGGCGACAGAAA Identification and mutation of the PA gene packaging signal, PR8 virus 5' packaging signal sequence, the mutated sequence: 5' packaging signal sequence 21: ctggaacctgggacctttgatcttggggggctatatgaagcaattgaggagtgcctgattaatgatccctgggttttgcttaatgcttcttggttcaactccttccttacacatgcattgagttag The mutated PA gene 5' packaging sequence 22: Ctcgagccaggaacgttcgacctaggaggactgtacgaggcgatcgaagaatgtctcataaacgacccttgggtattactaaacgcatcatggtttaactcgttcctgactcacgctttaagc Selection of monoclonal antibodies and gene sequences The antibody gene sequence used in the present invention is derived from the KEYTRUDA monoclonal antibody. This monoclonal antibody is IgG4, which is the PD1 therapeutic monoclonal antibody drug with the most tumor indications currently approved by the FDA. The amino acid sequence encoding the antibody is derived from IMGT.

[0020] StuI linearized pHW2000 vector, HA gene PCR product and various other gene PCR products were subjected to 1% agarose electrophoresis buffer respectively; the target fragment and vector were cut and recovered into a weighed 1.5ml EP tube, and purified using QIAEXII GelExtraction Kit: add 3 volumes of Buffer QX1 (100mg plus 300ul QX1). Add 30ul BufferQIAEX II and then water bath at 50°C for 10 minutes, vortexing every two minutes during this period. Centrifuge at 13000rpm for 30 seconds, discard the supernatant, add 500ul QIAEX I to wash once, add 500ul Buffer PE to wash twice, discard the supernatant, air dry for 15 minutes until the precipitate turns white. Add 20ulTE and vortex for 30 seconds and incubate for 5 minutes, centrifuge at 13000rpm for 30 seconds, transfer the supernatant into a 1.5ml EP tube, and measure the concentration.

[0021] According to the principle of Infusion technology, the linearized pHW2000 vector and HA and other gene fragments have 15 bases overlapped. Infusion technology can make them spliced ​​according to the overlapped parts. Using Clonetech's Infusion kit, the specific operation is as follows: 5 X In-Fusion buffer 2ul, Enzyme 1ul, linearized pHW200 vector, target gene fragment, water, total volume 10ul. The amount of vector and each fragment meets the molar ratio of 2:1. The Infusion mixture is treated at 37°C for 15 minutes and 50°C for 15 minutes. 40ul TE buffer is added to make up 50ul, and 2.5ul is taken to transform into DH5 alpha competent cells. The transformed competent cells are placed in ice for 30 minutes, heated at 42°C for 45 seconds, and then placed in ice for 1 minute. LB medium is added and shaken at 37°C for 60 minutes. Take 100ul of L-agar plate medium containing ampicillin, culture at 37℃ for 16 hours to form a single colony, pick a single colony and culture it in LB medium containing ampicillin for 8 hours, and use QIAprep Spin Miniprep Kit to extract plasmids from the bacterial solution after 8 hours of culture: pour the bacterial solution into a labeled 1.5ml centrifuge tube, centrifuge at 13000rpm, 4℃, for 3 minutes, discard the supernatant; add 250ul Buffer P1, mix well, add 250ul Buffer P2, quickly and gently invert 4-6 times; add 350ul Buffer N3, invert 4-6 times to mix, white flocs precipitate, 13000rpm, 4℃, 10 minutes; put the QIAprep spin column in a 1.5ml EP tube (to collect waste liquid) and then transfer the supernatant to the QIAprep spincolumn, 8000rpm 4℃, 1 minute; discard the waste liquid, add 750ul Buffer PE, 13000rpm, 4℃, 1 minute, discard the waste liquid, centrifuge at 13000rpm, 4℃, 1 minute, move the QIAprep spin column into a new 1.5ml centrifuge tube, add 30ul Buffer EB vertically on the membrane, let it stand for 1 minute, and centrifuge at 4℃, 13000rpm, 1min to obtain the liquid monoclonal plasmid.

[0022] The sequencing was correct and the recombinant vectors pHW2000-PR8_HA, pHW2000-PR8_NA, pHW2000-PR8_PB2, pHW2000-PR8_PB1, pHW2000-PR8_PA, pHW2000-PR8_NP, pHW2000-PR8_M, pHW2000-PR8_NS, pHW2000-PR8_PB1-VL and pHW2000-PR8_PA-VH were obtained.

[0023] Example 2 Transfection rescue virus The basic structure of influenza virus expressing human monoclonal antibodies is shown in Figure 1 and the basic structure of PD-1 monoclonal antibody gene is shown in Figure 2 Figure 1 and Figure 2 shown.

[0024] The recombinant vectors constructed in Example 1 were transfected into mixed cells of 293T cells according to the following combinations to package the recombinant virus rgH1N1(PR8)-pd1Ig (abbreviated as pd1Ig-IV).

[0025] Mixed vector: Mix 0.5 ug each of pHW2000-PR8_HA, pHW2000-PR8_NA, pHW2000-PR8_PB2, pHW2000-PR8_NP, pHW2000-PR8_M, pHW2000-PR8_NS, pHW2000-PR8_PB1-VL, and pHW2000-PR8_PA-VH to obtain the mixed vector A required for virus packaging; Take a bottle of 293T cells (ATCC-CRL-3216) T75 with good growth status, digest with 0.25% EDTA-trypsin, and centrifuge at 1000rpm for 10min. After centrifugation, break up and resuspend with 10mL of opti-MEM. Take the resuspended 293T and add opti-MEM to 20mL, take a 6-well plate, add 3mL of resuspended 293T cell suspension (5X104) to each well, and then put it into a 37℃ incubator for overnight culture.

[0026] Add 10ul of the mixed carrier A to the liposomes, place at room temperature for 20min, and then add opti-MEM to 1mL. Aspirate the waste liquid in the six-well plate, add opti-MEM mixed with plasmid, and place in a 37℃ 5% C02 incubator overnight. The next day, each well was supplemented with 1mL of opti-MEM containing 2ug / mL TPCK-Trypsin, and placed in a 37℃ 5% C02 incubator in a secondary biosafety laboratory for 48 hours to collect the cell suspension. The collected transfection supernatant is the P0 virus, and its hemagglutination titer is determined using 1% TRBC.

[0027] Select 9-day-old SPF chicken embryos and examine them to observe the vitality of the chicken embryos. Make a mark at the edge of the junction between the embryo surface and the air chamber, avoiding blood vessels and the head of the chicken embryo, which is the injection point. Disinfect the marked area and the surrounding area with 75% alcohol, and drill a hole with an egg drill without damaging the shell membrane.

[0028] The cell transfection suspension was inoculated into the allantoic cavity of chicken embryos at a volume of 0.2 mL / chicken embryo, and two chicken embryos were inoculated for each sample.

[0029] After sealing the chicken embryo with wax, place it in an incubator at 37°C for culture. After 48-72 hours, the chicken embryo allantoic fluid is harvested and the hemagglutination titer is determined using 1% turkey red blood cells (World Health Organization, Manual on Animal InfluenzaDiagnosis and Surveillance, Serologic diagnosis of influenza virus infections by hemagglutination inhibition, edition 4, 78-79, 2004). Hemagglutination-positive is the packaged recombinant virus rgIg-IV, and the virus generation is chicken embryo generation 1 (E1). The hemagglutination titers of the obtained recombinant viruses are all above 128HAU / 50L (i.e. 27).

[0030] The recombinant virus was continuously propagated for five generations by lysing chicken embryos, and the antibody gene was amplified and sequenced to verify that the antibody gene had no mutation; the virus hemagglutination titer, the VL and VH gene determination of the PB1 and PA genes, and the recombinant expression of monoclonal antibodies therein were tested as shown in Tables 1 and Figure 3 shown.

[0031] Table 1 Sequence changes, titers, antibody genes and antibody detection results during passage

[0032] Example 4 PD-1 Antibody Expressed by Recombinant Virus Expression of monoclonal antibodies The human IgG quantitative kit was used to quantitatively detect human IgG in the allantoic fluid after culturing chicken embryos for 48-72 hours. The results showed that the amount of recombinant monoclonal antibodies expressed in the allantoic fluid of an average chicken embryo after culturing at 33°C for 72 hours was about 10mL. The allantoic fluid of 15 chicken embryos was collected, about 150ml of allantoic fluid, and filtered with a 30kDa filter (Minipore) at 3000rpm and 4°C for 30 minutes. The supernatant retained after filtration was a mixture of antibodies and influenza viruses, about 500ul. After HA hemagglutination assay, the filtrate had no hemagglutination titer. The antibody and supernatant mixture was affinity purified by Protein A to obtain PD-1 monoclonal antibody.

[0033] The human IgG quantification method is as follows: coat with Goat Anti-Human Lambda (chain specific) [SouthernBiotech, CAT No: 2060-01], add the sample to be tested after BAS blocking and incubate at room temperature for 1 hour, wash 6 times with PBST and add HRP-Human IgG-Fc Fragment Antibody [Bethyl, CAT No: A80-104P], stop after color development and read the reading for determination.

[0034] The PD-1 protein expressed by 293T recombinant cells was coated in a 96-well plate (2ug / ml, 100ul / well), and then blocked with BAS overnight. The sample to be tested (chicken embryo allantoic fluid collected 48 hours after the recombinant influenza virus infected the chicken embryo) and the positive control antibody KEYTRUDA were added, reacted at room temperature for 1 hour, and then washed with PBST for 6 times. HRP-sheep anti-human secondary antibody was added, and the reading was performed after color development. The results are shown in Figure 4 , where Positive control is KEYTRUDA , Negative control is the purified product of allantoic fluid obtained by the same purification method.

[0035] Function of monoclonal antibodies expressed by recombinant viruses The same method was used to measure the PD-1 monoclonal antibody expressed by recombinant influenza virus in chicken embryos, and the results showed that its binding activity was no different from that of the PD-1 monoclonal antibody expressed in eukaryotic cells 293T.

Claims

1. A recombinant influenza virus expressing humanized PD-1 antibody, characterized in that: The recombinant influenza virus comprises a fusion gene PB1-PD-1-VL and a fusion gene PA-PD-1-VH; The fusion gene PB1-PD-1-VL includes, from the 5' end, the PB1 gene, the mutated PB-1 packaging sequence, the FMDV-2A sequence, the signal peptide sequence, the PD-1 human antibody VL gene, and the light chain kappa gene; The fusion gene PA-PD-1-VH includes, from the 5' end, the PA gene, the mutated PA packaging sequence, the FMDV-2A sequence, the signal peptide sequence, the PD-1 human antibody VH gene, the heavy chain CH1 gene and the Fc gene.

2. The recombinant influenza virus according to claim 1, wherein: The PB1 gene sequence of the fusion gene PB1-PD-1-VL is shown in SEQ ID NO.4, the mutated PB-1 packaging sequence is shown in SEQ ID NO.14, the FMDV-2A sequence is shown in SEQ ID NO.15, and the signal peptide sequence is shown in SEQ ID NO.16; The PA gene sequence of the fusion gene PA-PD-1-VH is shown in SEQ ID NO.5, the mutated PA packaging sequence is shown in SEQ ID NO.9, the FMDV-2A sequence is shown in SEQ ID NO.10, and the signal peptide sequence is shown in SEQ ID NO.

11.

3. The recombinant influenza virus according to claim 1, wherein the humanized PD-1 antibody is KEYTRUDA.

4. The recombinant influenza virus according to claim 3, wherein: The PD-1 human antibody VL gene of the fusion gene PB1-PD-1-VL is shown in SEQ ID NO.17, and the light chain kappa gene is shown in SEQ ID NO.18; The PD-1 human antibody VH gene of the fusion gene PA-PD-1-VH is shown in SEQ ID NO.12, and the heavy chain CH1 gene and Fc gene are shown in SEQ ID NO.

13.

5. The recombinant influenza virus according to claim 1, further comprising influenza virus PB2, HA, NP, NA, M and NS genes.

6. A method for preparing a recombinant influenza virus according to any one of claims 1 to 5, characterized in that: The method is to rescue and prepare a recombinant influenza virus expressing a humanized PD-1 antibody through an eight-plasmid reverse genetics system.

7. The method according to claim 6 comprises mixing a plasmid carrying influenza virus PB2, HA, NP, NA, M and NS genes and a plasmid carrying fusion gene PB1-PD-1-VL and fusion gene PA-PD-1-VH with liposomes and then incubating with 293T cells.

8. Use of the recombinant influenza virus according to any one of claims 1 to 5 in the preparation of a drug for treating cancer.

9. The use according to claim 8, wherein the cancer is a PD-1 associated cancer.

10. Use of the recombinant influenza virus according to any one of claims 1 to 5 in the preparation of humanized PD-1 antibodies.

Citation Information

Patent Citations

  • Site specific incorporation of non-natural amino acids by vertebrate cells

    CN101528914A

  • Recombinant influenza virus and application thereof

    CN104312983A

  • Anti-human PD-L1 / KIR bispecific antibody, preparation method and application thereof

    CN105669862A

  • PD-1 antibodies

    CN108473977A

  • Recombinant influenza virus rescue method and application of the same in tumor therapy

    CN109913425A